^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Aventa FusionPlus Test

Type:
Laboratory Developed Test
Evidence

News

2ms
Validation of Aventa FusionPlus: An LDT NGS assay for comprehensive cancer genomic profiling (AACR 2024)
As an example, in a breast cancer case, a fusion of genomic regions neighboring BRAF and MYC oncogenes on chromosomes 7 and 8 respectively, was missed by the reference method but was successfully detected by the Aventa FusionPlus test.The Aventa FusionPlus test is a highly sensitive, specific, and accurate method for comprehensive cancer genomic profiling. The enhanced understanding of gene fusions and rearrangements positions the test as a valuable tool for clinical decision-making in oncology.
Next-generation sequencing
|
BRAF (B-raf proto-oncogene)
|
Aventa FusionPlus Test
8ms
Aventa Genomics Announces Launch of Aventa FusionPlus, the First 3D Genomics Clinical Test for Patients with Solid Cancers (Businesswire)
"Aventa™ Genomics, LLC...announced the launch of Aventa FusionPlus, a next-generation sequencing (NGS) test for the detection of gene fusions, translocations, and rearrangements across 361 genes from formalin-fixed, paraffin embedded (FFPE) tumor tissue. Aventa’s testing service is performed in its CLIA-certified laboratory in Orlando, Florida."
Launch
|
Aventa FusionPlus Test